Labiotech.eu

News and Trends 17 Jul 2017

A Brand New Outlook on Induced Pluripotent Stem Cells

In an exclusive interview with Dr David Hallett, we discover why iPS cells are the perfect replacement for human embryonic stem cells, what is so unique about them and the challenges researchers face in the field! Talk of using human stem cells to better understand and even cure diseases has been around for a few decades. […]

July 17, 2017 - 8 minutesmins - By External Contributor

Interview 17 Jul 2017

Pinning Down Elusive Targets: Interviewing the Co-Founder & CSO of Heptares

Heptares is expanding into a range of indications with its GPCR platform. I caught up with CSO & co-founder Fiona Marshall to hear more about the strategy. Fiona Marshall has always worked on G-protein coupled receptors, or GPCRs for short. These entities are key to many eukaryotic signaling pathways, and because of their prevalence, they’re […]

July 17, 2017 - 6 minutesmins - By Evelyn Warner

More News! 15 Jul 2017

Speculative Biology in Art: How will Life Look like in the Future?

The first solo exhibition of Turkish artist Pinar Yoldas imagines a future where biology is shaped by climate change and plastic pollution. Last week in Amsterdam opened Carboniferous, a solo bioart exhibition by Pinar Yoldas focusing on speculative biology. This concept revolves around imagining how life will evolve according to predictions of how the planet’s future ecosystems […]

July 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 13 Jul 2017

Video: How to Access EU Funding as an Innovative Biotech

Two experts, one success story. From the European Commission to the European Investment Bank, our experts told us what to do to access EU funding as an innovative and young Biotech company! This Refresh Expert Track kicked off with the Head of Unit at the European Commission, Cornelius Schmaltz, who introduced the focus for health research […]

July 13, 2017 - 2 minutesmins - By External Contributor

News and Trends 13 Jul 2017

Why European Biotech Startups Should Attend American Conferences!

We all know conferences are important. To be on the same page, let’s brainstorm the word. What comes to mind? A long list of associations – networking, partnering, businesses, meetings, new people, knowledge, presentations, talks, panels, companies. We could go on and on – one thing is clear: they are one of the most effective […]

July 13, 2017 - 6 minutesmins - By External Contributor

Interview 13 Jul 2017

Meet Denmark’s Youngest Professor and Serial Synbio Entrepreneur

Philip sat down to chat with Professor and serial entrepreneur Morten Sommer about his career in the second Labiotech Hangout. At 35, Morten Sommer is not only the youngest full professor ever in Denmark but also the entrepreneur behind a number of synbio-based companies. For Labiotech’s second Hangout on June 29th, Philip probed his thoughts […]

July 13, 2017 - 4 minutesmins - By Evelyn Warner

inflammatory disease imperial college london macrophage

News and Trends 12 Jul 2017

British Researchers “Calm Down” Macrophages to treat Inflammation

Imperial College London and Ergon Pharmaceuticals have a new enzyme target to treat inflammatory disease by reducing the activity of macrophages. Researchers at Imperial College London have developed a method to reprogram macrophages and reduce their inflammatory activity. The approach, published in Nature Communications, proved to reduce by more than half inflammation in the joints […]

July 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

genetically modified mosquitoes Oxitec Netherlands

News and Trends 12 Jul 2017

Update: France and the Netherlands deem Oxitec’s GM Mosquitoes Safe for Release

Update (12/07/2017): France’s High Council for Biotechnology (HCB) has also backed the use, with caution, of genetically modified mosquitoes in France. Oxitec expects the report published by the HCB will help shape the policy to regulate the genetically engineered insects in France and eventually allow testing the technology in the French Caribbean. Originally published on 07/07/2017 A […]

July 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Erytech pharma Queens university red blood cells

News and Trends 12 Jul 2017

French Biotech and Canadian University to treat Rare Disease with Red Blood Cells

Erytech Pharma has entered a partnership with Queen’s University to treat the rare disease arginase-1 deficiency using engineered red blood cells. Erytech, based in Lyon, is known for its unique technology for drug delivery. Its most advanced program, in Phase IIb for metastatic pancreatic cancer, employs red blood cells engineered to produce the enzyme L-asparaginase, which depletes […]

July 12, 2017 - 1 minutemin - By Clara Rodríguez Fernández

In Depth 12 Jul 2017

Genomic Testing in Oncology: From Single Genes to Whole Genomes

Personalized medicine would be nothing without genomic testing tools. Here’s an overview of how the field has rapidly evolved in the past years. BRCA (BReast CAncer) is one of the most famous gene variants for breast cancer testing. But aside from being a game-changer from a scientific perspective, it also changed the laws of genomic testing. […]

July 12, 2017 - 5 minutesmins - By Timothé Cynober

Interview 11 Jul 2017

The Advantage for the First Mover in NASH is Limited, says Genfit

After we reviewed NASH earlier this year, Genfit’s CSO, Dean Hum, came to speak at Refresh about his company’s strategy in the space. As CSO of Genfit, Dean Hum coordinates the company’s R&D efforts to be first to market in NASH, which represent an untapped market of €37B. The company is counting on its lead […]

July 11, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 11 Jul 2017

Finnish AI Biotech Raises €14M to Open the Bottleneck of Next-Generation Sequencing

Blueprint Genetics has raised €14M to boost its genetic diagnostics platform, using artificial intelligence to interpret next-generation sequencing data. Based in Helsinki, Finland, Blueprint Genetics is a startup that addresses the main bottleneck of genetic testing through next-generation sequencing (NGS), the interpretation of massive volumes of data, with the aid of artificial intelligence (AI). Its […]

July 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

A Brand New Outlook on Induced Pluripotent Stem Cells

Pinning Down Elusive Targets: Interviewing the Co-Founder & CSO of Heptares

Speculative Biology in Art: How will Life Look like in the Future?

Video: How to Access EU Funding as an Innovative Biotech

Why European Biotech Startups Should Attend American Conferences!

Meet Denmark’s Youngest Professor and Serial Synbio Entrepreneur

British Researchers “Calm Down” Macrophages to treat Inflammation

Update: France and the Netherlands deem Oxitec’s GM Mosquitoes Safe for Release

French Biotech and Canadian University to treat Rare Disease with Red Blood Cells

Genomic Testing in Oncology: From Single Genes to Whole Genomes

The Advantage for the First Mover in NASH is Limited, says Genfit

Finnish AI Biotech Raises €14M to Open the Bottleneck of Next-Generation Sequencing

Subscribe to our newsletter to get the latest biotech news!